• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

卵巢癌中存在大量p53基因无效突变。

An abundance of p53 null mutations in ovarian carcinoma.

作者信息

Skilling J S, Sood A, Niemann T, Lager D J, Buller R E

机构信息

Department of Obstetrics and Gynecology, University of Iowa Hospitals and Clinics, Iowa City, 52242, USA.

出版信息

Oncogene. 1996 Jul 4;13(1):117-23.

PMID:8700537
Abstract

Ovarian cancers from 64 midwestern US women were screened for p53 dysfunction both by immunohistochemical staining (IHCS) and single strand conformation polymorphism (SSCP) analysis of the entire open reading frame (ORF). Forty SSCP abnormalities in 39 tumors included nine deletion, one insertion, two splice junction, two nonsense, one silent and 25 missense mutations were confirmed by direct genomic sequencing. Eight of the insertion/deletion defects may have occurred due to slippage during the course of DNA replication. This observation suggests that genomic instability may play an important role in ovarian carcinogenesis. Fifteen percent of the mutations encountered were located outside exons 5-9 and four of these were null. The sensitivity of IHCS was 96% for missense mutations but only 14% for null mutations. This contrasted with 100% sensitivity of the SSCP screening methodology. The 21% overall incidence of null mutations in the present study far exceeds the reported 6.8% incidence in the world literature (P=0.0003). Explanations for this difference include: (1) our complete analysis of the entire ORF of the p53 gene; (2) the tendency of others to rely upon IHCS to screen tumors prior to mutation analysis; and (3) environmental or endogenous genetic influences.

摘要

对来自美国中西部64名女性的卵巢癌进行了p53功能障碍筛查,采用免疫组织化学染色(IHCS)和对整个开放阅读框(ORF)进行单链构象多态性(SSCP)分析的方法。39个肿瘤中的40个SSCP异常包括9个缺失、1个插入、2个剪接位点、2个无义、1个沉默和25个错义突变,经直接基因组测序得以证实。8个插入/缺失缺陷可能是由于DNA复制过程中的滑动所致。这一观察结果表明,基因组不稳定性可能在卵巢癌发生过程中起重要作用。所遇到的突变中有15%位于外显子5 - 9之外,其中4个为无效突变。IHCS对错义突变的敏感性为96%,但对无效突变仅为14%。这与SSCP筛查方法100%的敏感性形成对比。本研究中无效突变的总体发生率为21%,远远超过世界文献报道的6.8%的发生率(P = 0.0003)。造成这种差异的原因包括:(1)我们对p53基因整个ORF的完整分析;(2)其他人在进行突变分析之前倾向于依靠IHCS来筛查肿瘤;以及(3)环境或内源性遗传影响。

相似文献

1
An abundance of p53 null mutations in ovarian carcinoma.卵巢癌中存在大量p53基因无效突变。
Oncogene. 1996 Jul 4;13(1):117-23.
2
Distant metastases in ovarian cancer: association with p53 mutations.卵巢癌的远处转移:与p53基因突变的关联。
Clin Cancer Res. 1999 Sep;5(9):2485-90.
3
p53 mutation is infrequent in clear cell carcinoma of the ovary.p53突变在卵巢透明细胞癌中并不常见。
Gynecol Oncol. 2001 Feb;80(2):189-93. doi: 10.1006/gyno.2000.6025.
4
High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.台湾肺癌鳞状细胞癌患者p53基因缺失突变的高频率
Cancer Res. 1998 Jan 15;58(2):328-33.
5
p53 and Ki-ras gene mutations in epithelial ovarian neoplasms.上皮性卵巢肿瘤中的p53和Ki-ras基因突变
Cancer Res. 1993 Jul 1;53(13):3103-8.
6
Ovarian cancer genomic instability correlates with p53 frameshift mutations.
Cancer Res. 1997 Mar 15;57(6):1047-9.
7
Mutations of p53 gene in gastric carcinoma in Taiwan.台湾地区胃癌中p53基因的突变
Anticancer Res. 2001 Jan-Feb;21(1B):513-20.
8
P53 mutations in colorectal cancer assessed in both genomic DNA and cDNA as compared to the presence of p53 LOH.与p53杂合性缺失的存在情况相比,在基因组DNA和互补DNA中评估的结直肠癌中的P53突变。
Int J Oncol. 2002 Aug;21(2):409-15.
9
p53 gene mutations in human urothelial carcinomas: analysis by immunohistochemistry and single-strand conformation polymorphism.人尿路上皮癌中的p53基因突变:免疫组织化学和单链构象多态性分析
Mod Pathol. 1995 Feb;8(2):170-6.
10
Alterations of p53 gene in primary gastric cancer tissues.
Anticancer Res. 1994 May-Jun;14(3B):1251-5.

引用本文的文献

1
Identification of MAD2L1 and BUB1B as Potential Biomarkers Associated with Progression and Prognosis of Ovarian Cancer.鉴定MAD2L1和BUB1B作为与卵巢癌进展和预后相关的潜在生物标志物。
Biochem Genet. 2024 Apr 29. doi: 10.1007/s10528-024-10817-2.
2
Complexity of the Genetic Background of Oncogenesis in Ovarian Cancer-Genetic Instability and Clinical Implications.卵巢癌发生中遗传背景的复杂性——遗传不稳定性及其临床意义。
Cells. 2024 Feb 15;13(4):345. doi: 10.3390/cells13040345.
3
Immunohistochemical Profiling of PD-1, PD-L1, CD8, MSI, and p53 and Prognostic Implications in Advanced Serous Ovarian Carcinoma: A Retrospective Study.
晚期浆液性卵巢癌中PD-1、PD-L1、CD8、微卫星不稳定性(MSI)及p53的免疫组化分析及其预后意义:一项回顾性研究
J Pers Med. 2023 Jun 26;13(7):1045. doi: 10.3390/jpm13071045.
4
A Comprehensive Review of Ovarian Serous Carcinoma.卵巢浆液性癌的全面综述。
Adv Anat Pathol. 2019 Sep;26(5):329-339. doi: 10.1097/PAP.0000000000000243.
5
Development of a Bioluminescent BRCA1-Deficient Xenograft Model of Disseminated, High-Grade Serous Ovarian Cancer.BRCA1 缺陷型生物发光异种移植模型在播散性高级别浆液性卵巢癌中的构建。
Int J Mol Sci. 2019 May 21;20(10):2498. doi: 10.3390/ijms20102498.
6
Pharmacologic inhibition of ATR and ATM offers clinically important distinctions to enhancing platinum or radiation response in ovarian, endometrial, and cervical cancer cells.对ATR和ATM进行药理学抑制,在增强卵巢癌、子宫内膜癌和子宫颈癌细胞对铂类药物或放疗的反应方面具有重要的临床意义。
Gynecol Oncol. 2015 Mar;136(3):554-61. doi: 10.1016/j.ygyno.2014.12.035. Epub 2015 Jan 2.
7
Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.卵巢癌的流行病学和筛查的现代趋势。散发性形式的遗传基础。
Pathol Oncol Res. 2012 Apr;18(2):135-48. doi: 10.1007/s12253-011-9482-8. Epub 2011 Dec 9.
8
Microenvironment and pathogenesis of epithelial ovarian cancer.上皮性卵巢癌的微环境与发病机制。
Horm Cancer. 2010 Dec;1(6):277-90. doi: 10.1007/s12672-010-0054-2.
9
Genomic aberrations in borderline ovarian tumors.交界性卵巢肿瘤的基因组异常。
J Transl Med. 2010 Feb 26;8:21. doi: 10.1186/1479-5876-8-21.
10
The role of p53 as a surrogate marker for chemotherapeutical responsiveness in ovarian cancer.p53 作为卵巢癌化疗反应替代标志物的作用。
J Cancer Res Clin Oncol. 2010 Jan;136(1):79-88. doi: 10.1007/s00432-009-0639-8.